The obesity treatment landscape is rapidly evolving beyond GLP-1 drugs, with researchers exploring new therapies designed to prevent weight regain, improve long-term maintenance, reduce side effects, and preserve muscle mass after treatment discontinuation.
At the 2026 ADA Scientific Sessions, investigators presented several early-stage approaches, including an oral TXNIP inhibitor that prevented post-semaglutide weight rebound in animal models, a long-acting GIP receptor antagonist designed for weight maintenance, a four-target obesity drug that outperformed tirzepatide in preclinical studies, and a combination of dorzagliatin with oral GLP-1 therapy that improved glucose control while maintaining weight loss. Together, the studies highlight growing efforts to address one of obesity medicine’s biggest challenges: sustaining weight loss after GLP-1 therapy ends.
A related analysis also found that patients who discontinue GLP-1 therapies often regain weight rapidly, prompting interest in alternative maintenance strategies such as endoscopic sleeve gastroplasty and new oral medications like orforglipron.